Therefore, HOXB5 was a potential prognostic biomarker in HCC patients and targeting the oncogenic FGF19-HOXB5-FGFR4 loop may provide a promising treatment strategy for HOXB5-upregulated HCC subpopulation. This evidence concerns the gene FGF19 and hepatocellular carcinoma.